Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2009-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the developing world.
* It is believed that understanding the complex interplay between genetic and lifestyle characteristics in the etiology of T2D and related complications will lead to the development of better preventive and therapeutic strategies. In Addition, the results of this project will facilitate our understanding of causes of diabetes in African Americans, other US and world populations
Objectives:
* To conduct a genome-wide association study (GWAS) to identify susceptibility genetic variants for diabetes among the Yoruba people in Ibadan, Nigeria.
* To enroll and examine 300 unrelated cases of T2D and 300 ethnicity-matched Yoruba controls.
* To conduct resequencing of positional candidate gene/loci to identify likely functional variants in a subset of the cohort.
* To conduct replication studies of the top-100 scoring variants in three independent African and European ancestry samples.
* To investigate whether diabetes-associated variants discovered in European populations increase diabetes risk in West Africans.
Eligibility:
* Patients 18 years of age with confirmed T2D who are newly diagnosed or on treatment of Yoruba ethnicity in Ibadan, Nigeria. Control subjects are nondiabetics ethnically matched to patients.
Design:
* The study design for both patients and controls consists of the following steps:
* Discuss informed consent process and obtain signed informed consent form. Informed consent will be administered by trained clinic staff.
* Assign study ID (barcode)
* Administer questionnaires
* Obtain spot urine sample
* Measure blood pressure
* Obtain anthropometric measurements including body composition
* Perform finger prick for blood glucose level
* Obtain venous blood samples
* Perform eye examination
* On the following day, perform confirmatory blood glucose for the small subset of participants requiring confirmation of previous test result DNA extraction of stored samples will be done at either the National Institutes of Health or the laboratory in Nigeria.
* GWAS will be conducted using publicly available software packages.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This protocol is designed to study the genetic basis of Type 2 Diabetes (T2D) and related conditions in Africa.
Objectives:
Primary Objective: To conduct genetic association studies of T2D, T2D complications, and related traits in Africans of diverse ethnic groups
Secondary Objectives:
* To investigate the contribution of gene x environment interactions in T2D risk and in influencing related traits
* To develop a large-scale genetic epidemiological resource for the replication of findings in other studies of related traits
* To conduct trans-ethnic fine-mapping
* To describe the study population epidemiologically in terms of cardiometabolic traits and prevalence of related conditions
* To conduct population genetic analyses to describe population history and to develop statistical techniques appropriate for genetic analyses of African ancestry individuals
* To conduct deep phenotyping to facilitate additional research questions related to cardiometabolic traits and for follow-up previous findings
Endpoints:
Primary Endpoint: T2D
Secondary Endpoints: T2D Complications, Hypertension, Obesity, Dyslipidemia, Metabolic Syndrome, Chronic Kidney Disease, and other cardiometabolic traits
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Control subjects are nondiabetics ethnically matched to patients
No interventions assigned to this group
T2D
Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
We are seeking to enroll persons without T2D or with previously or newly diagnosed T2D. Previously diagnosed cases will be determined by self-report of being treated with oral medication or insulin. Newly diagnosed cases will be determined by fasting blood glucose value \>= 126 mg/dl on more than one occasion. Individuals who have elevated blood glucose during their initial reading will be asked to return to the study site for a second test. If this test also has a fasting blood glucose value \>= 126 mg/dl, then they will be considered a new case. The control group will be individuals with no report of T2D diagnosis and fasting plasma glucose (FPG)\< 126 mg/dl.
Only unrelated individuals will be included in this phase of the study to avoid confounding genetic association studies by relatedness in the study population.
Exclusion Criteria
* Incarceration.
* Lack capacity to consent to research participation.
* Pregnancy.
18 Years
120 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Human Genome Research Institute (NHGRI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles N Rotimi, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Human Genome Research Institute (NHGRI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Ghana
Accra, , Ghana
University of Science and Tech
Kumasi, , Ghana
University of Nigeria
Enugu, , Nigeria
University of Ibadan
Ibadan, , Nigeria
University of Lagos
Lagos, , Nigeria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clement Adebamowo, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-HG-N070
Identifier Type: -
Identifier Source: secondary_id
999909070
Identifier Type: -
Identifier Source: org_study_id